ArticleInternational journal of clinical and experimental pathology2017
Proteomic identification of candidate plasma biomarkers for preeclampsia in women with pregnancy-induced hypertension.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities.Frontiers in immunology · 2024Pooled it
- The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions.Clinical and experimental immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE), a complication of pregnancy, is the leading cause of maternal and perinatal morbidity and mortality and seriously impacts maternal and child health. This study aimed to characterize biomarkers for the early diagnosis of PE. We performed a comparative proteomic analysis on the plasma obtained from PE and healthy pregnant women. We analyzed the plasma samples using two-dimensional differential gel electrophoresis (2D-DIGE) coupled with Ultraflex III, a MALDI-TOF-TOF (matrix-assisted laser desorption/ionization-time-of-flight) mass spectrometer and identified differentially expressed proteins (DEPs). We analyzed the abundance levels of these DEPs by enzyme-linked immunosorbent assay (ELISA) to further confirm their role as putative PE biomarkers. We identified a total of 56 DEPs, of which 48 were down-regulated and 8 were up-regulated in women with PE. The identities of 8 of these DEPs were characterized by mass spectrum analysis, including LG3BP (lectin, galactoside-binding, soluble, 3 binding protein), APOA1 (apolipoprotein A-I), FETUA (alpha-2-HS-glycoprotein), CFAI (complement factor I), CD5L (CD5 antigen-like), K2C6A (keratin, type II cytoskeletal 6A), PON1 (paraoxonase/arylesterase 1) and HP1 (haptoglobin). Finally, the differential expression of these 8 proteins was verified by ELISA. In summary, we applied the 2D-DIGE and Ultraflex III-TOF/TOF platform to identify potential plasma biomarkers of PE. Of these, plasma LG3BP, APOA1, FETUA, CFAI, CD5L, K2C6A, PON1 and HP1 were promising candidates for predicting PE.
Indexed as
Identifiers
31966374PMC6965753W3027469462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.